Article
Oncology
Deepti Gadi, Alec Griffith, Svitlana Tyekucheva, Zixu Wang, Vanessa Rai, Alexander Vartanov, Emily Thrash, Stacey M. Fernandes, Timothy Z. Lehmberg, Brandon Lee, Stephen P. Martindale, John-Hanson Machado, Oreofe Odejide, Philippe Armand, David C. Fisher, Jon Arnason, Matthew S. Davids, James A. Lederer, Jennifer R. Brown
Summary: Combination therapy with the PI3K delta gamma inhibitor duvelisib and chemoimmunotherapy shows promising efficacy in treating CLL patients, but approximately one-third of patients develop autoimmune toxicity. The treatment modulates CD4 and CD8 T cell subsets as well as pro-inflammatory cytokines, resulting in an increase in activated CD8 T cells and Th17 T cells.
Article
Biochemistry & Molecular Biology
Christopher P. Hedges, Jordi Boix, Jagdish K. Jaiswal, Bhoopika Shetty, Peter R. Shepherd, Troy L. Merry
Summary: BYL719 delivered through diet effectively suppresses insulin signaling and maintains long-term efficacy without affecting food intake and other physiological indicators.
Review
Oncology
Motahareh Mortazavi, Fatemeh Moosavi, Miriam Martini, Elisa Giovannetti, Omidreza Firuzi
Summary: This study highlights the role of PI3K/AKT/mTOR pathway in pancreatic ductal adenocarcinoma, but clinical studies have not been promising. Patient stratification is identified as a crucial factor.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Hematology
Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown
Summary: Resistance to PI3K delta inhibitors in CLL is associated with baseline activating mutations and activation of the MAPK/ERK pathway, suggesting a rationale for combination therapy with PI3K delta and ERK inhibitors.
Article
Multidisciplinary Sciences
Fu-Cheng Chuang, Chih-Chun Wang, Jian-Han Chen, Tzer-Zen Hwang, Shyh-An Yeh, Yu-Chieh Su
Summary: The study identified that pan-PI3K inhibitors can enhance radiosensitivity of OSCC cells, suggesting potential therapeutic agents for patients with OSCC.
Article
Oncology
Yaya Yu, Zhenzhen Xiao, Chenjing Lei, Changju Ma, Lina Ding, Qing Tang, Yihan He, Yadong Chen, Xuesong Chang, Yanjuan Zhu, Haibo Zhang
Summary: Non-small cell lung cancer (NSCLC) patients with EGFR mutation often develop resistance to EGFR-TKIs due to the activation of PI3K/AKT signaling pathway. Combination of BYL719 and gefitinib, inhibitors of PI3K and EGFR-TKI respectively, showed synergistic effects in EGFR-mutated NSCLC cells with PI3K/AKT activation, providing a promising therapeutic approach to overcome EGFR-TKIs resistance induced by PI3K/AKT activation.
Editorial Material
Hematology
Nathan Fowler
Summary: Mato et al. reported the results of a phase 2 study on umbralisib, a PI3K inhibitor, in CLL patients who were intolerant of BTK inhibitors. The study suggests that umbralisib may be effective for CLL patients who cannot tolerate BTK inhibitors.
Article
Immunology
Lisa Rohrbacher, Bettina Brauchle, Ana Ogrinc Wagner, Michael von Bergwelt-Baildon, Veit L. Bucklein, Marion Subklewe
Summary: Idelalisib is a highly selective inhibitor of PI3K p110 isoform, affecting T and NK cells by reducing cytotoxicity and cytokine secretion levels. This may contribute to an increased risk of infection in patients, despite its therapeutic success being hindered by severe opportunistic infections.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay R. Mohan, Tess Stopczynski, Sheau-Chiann Chen, Run Fan, Yuankai Huo, Hyeonsoo Moon, Yucheng Tang, Cosmin A. Bejan, Merrida Childress, Ingrid Anderson, Kyle Rawling, Rhea M. Simons, Ashley Moncrief, Rebekah Caza, Laura Dugger, Aunshka Collins, Channing Dudley, P. Brent Ferrell, Michael Byrne, Stephen A. Strickland, Gregory D. Ayers, Bennett A. Landman, Emily F. Mason, Ruben A. Mesa, Jeanne M. Palmer, Laura C. Michaelis, Michael R. Savona
Summary: This study evaluated the safety and efficacy of a combination treatment of a selective PI3KS inhibitor, umbralisib, and a JAK inhibitor, ruxolitinib, for patients with MF. The results showed that the combination treatment was well tolerated and could potentially resensitize patients to ruxolitinib.
CLINICAL CANCER RESEARCH
(2023)
Article
Biology
Floyd Hassenrueck, Maria Farina-Morillas, Lars Neumann, Francesco Landini, Stuart James Blakemore, Mina Rabipour, Juan Raul Alvarez-Idaboy, Christian P. Pallasch, Michael Hallek, Rocio Rebollido-Rios, Guenter Krause
Summary: Cell-based and molecular exploration provides comparative characterization of currently developed PI3K inhibitors and structural insights for future inhibitor design. The study focuses on targeting the PI3K isoform p110 delta against B cell malignancies and evaluates the potency, isoform-selectivity, and molecular interactions of various PI3Ki chemotypes. The I777M substitution affects the efficacy and selectivity of p110 delta-selective inhibitors, but not multi-targeted inhibitors, due to its effect on the conformational flexibility of p110 delta's specificity or affinity pockets. This research provides valuable information for optimizing PI3Ki design.
COMMUNICATIONS BIOLOGY
(2023)
Article
Multidisciplinary Sciences
Ninghui Mao, Zeda Zhang, Young Sun Lee, Danielle Choi, Aura Agudelo Rivera, Dan Li, Cindy Lee, Samuel Haywood, Xiaoping Chen, Qing Chang, Guotai Xu, Hsuan-An Chen, Elisa de Stanchina, Charles Sawyers, Neal Rosen, Andrew C. Hsieh, Yu Chen, Brett S. Carver
Summary: Understanding the mechanisms driving PI3K isoform dependency in prostate cancer can help in designing effective clinical trials. Mutations in PIK3CA or PIK3CB can result in PI3K p110 isoform dependency, with direct inhibition of AKT potentially being more effective than PI3K inhibition in PTEN-deficient prostate cancers. Selective targeting of specific PI3K isoforms based on contextual factors like PTEN status and PIK3CA/PIK3CB alterations may offer novel therapeutic strategies.
NATURE COMMUNICATIONS
(2021)
Article
Endocrinology & Metabolism
Siyoung Ha, Himali Gujrati, Bi-Dar Wang
Summary: Our study has identified PI3Kδ-S as an oncogenic isoform that is resistant to drugs and independent of PTEN regulation, making it a potential prognostic biomarker and drug target in endocrine cancers.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Iwona Hus, Bartosz Pula, Tadeusz Robak
Summary: The development of small agents targeting the B-cell receptor (BCR) pathway has greatly improved the treatment of chronic lymphocytic leukemia (CLL). Selective inhibitors of PI3K delta, such as idelalisib and duvelisib, have been approved for CLL treatment. Umbralisib, a selective inhibitor of PI3K delta and CK1 epsilon, has shown promising results in combination regimens in clinical trials for CLL treatment.
Review
Immunology
Ebru Aydin, Sebastian Faehling, Mariam Saleh, Laura Llao Cid, Martina Seiffert, Philipp M. Roessner
Summary: PI3K pathway plays a crucial role in cell growth and malignant transformation, with its hyperactivation being a hallmark of cancer. Inhibiting PI3K not only affects cancer cells but also impacts the tumor microenvironment and immune cell function. Understanding the effects of PI3K inhibition on the tumor microenvironment in CLL can lead to improved drug development and novel combinatory treatment strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Thomas D. Rodgers, AnnaLynn M. Williams, Andrea Baran, Patrick M. Reagan, Carla Casulo, Clive S. Zent, Andrew Evans, Jonathan W. Friedberg, Paul M. Barr
Summary: A retrospective review of 79 patients found that patients receiving novel combination therapy and previously untreated patients were more likely to develop severe adverse events. This suggests caution against the use of untested PI3K inhibitor combinations in routine practice.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Massimo Fantini, Justin M. David, Hing C. Wong, Christina M. Annunziata, Philip M. Arlen, Kwong Y. Tsang
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
(2019)
Article
Medicine, Research & Experimental
Daniel S. Green, Ana T. Nunes, Kevin W. Tosh, Virginia David-Ocampo, Vicki S. Fellowes, Jiaqiang Ren, Jianjian Jin, Sue-Ellen Frodigh, Chauha Pham, Jolynn Procter, Celina Tran, Irene Ekwede, Hanh Khuu, David F. Stroncek, Steven L. Highfill, Kathryn C. Zoon, Christina M. Annunziata
JOURNAL OF TRANSLATIONAL MEDICINE
(2019)
Article
Oncology
Mary L. Disis, Matthew H. Taylor, Karen Kelly, J. Thaddeus Beck, Michael Gordon, Kathleen M. Moore, Manish R. Patel, Jorge Chaves, Haeseong Park, Alain C. Mita, Erika P. Hamilton, Christina M. Annunziata, Hans Juergen Grote, Anja von Heydebreck, Jaspreet Grewal, Vikram Chand, James L. Gulley
Meeting Abstract
Oncology
Maria Pia Morelli, Justin M. David, Nicole D. Houston, Stan Lipkowitz, Jung-min Lee, Alexandra Dos Santos Zimmer, Farah Z. Zia, Irene Ekwede, Erin Nichols, Mira Pavelova, Rebecca Trupp, Stephen M. Hewitt, Massimo Fantini, Philip M. Arlen, Kwong Y. Tsang, Christina M. Annunziata
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Oncology
Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston, Jung-Min Lee
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2019)
Article
Oncology
Jung-Min Lee, Dana-Adriana Botesteanu, Yusuke Tomita, Akira Yuno, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Ursula Matulonis, Lauren A. MacDonald, Jayakumar R. Nair, Kimberley M. Macneill, Jane B. Trepel
Review
Oncology
Brittney S. Harrington, Christina M. Annunziata
Article
Oncology
Anne M. Noonan, Amanda Cousins, David Anderson, Kristen P. Zeligs, Kristen Bunch, Lidia Hernandez, Yusuke Shibuya, Ian S. Goldlust, Rajarshi Guha, Marc Ferrer, Craig J. Thomas, Christina M. Annunziata
Editorial Material
Oncology
Amy E. Turriff, Christina M. Annunziata, Diana W. Bianchi
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Kwong Yok Tsang, Massimo Fantini, Sharon A. Mavroukakis, Anjum Zaki, Christina M. Annunziata, Philip M. Arlen
Summary: This article describes a tumor-targeting monoclonal antibody called NEO-201, which can inhibit tumor growth through multiple mechanisms. NEO-201 kills tumor cells by engaging with immune cells through antibody-dependent cell-mediated cytotoxicity and complement dependent cytotoxicity, and it can also block interactions between tumor cells and other cells to enhance anti-cancer activity.
Article
Oncology
Kwong Y. Tsang, Massimo Fantini, Anjum Zaki, Sharon A. Mavroukakis, Maria Pia Morelli, Christina M. Annunziata, Philip M. Arlen
Summary: Glycosylation is an important post-translational modification that occurs on mammalian proteins and lipids. Disruption of O-glycosylation patterns, especially the truncation of O-glycans, has been observed in cancer cells. Monoclonal antibodies targeting truncated O-glycans in cancer cells can be an effective strategy to counter tumor growth.
Meeting Abstract
Oncology
C. Annunziata, C. Dansky-Ullmann, A. Ghobadi, D. Weng, J. Vanas, I. Ekwede, M. Pavelova, R. Keefe, M. Kuo, R. Hassan, P. Thaker
ANNALS OF ONCOLOGY
(2019)
Meeting Abstract
Oncology
Anna Duemler, Daniel S. Green, Steven L. Highfill, David Stroncek, Kathryn Zoon, Christina M. Annunziata
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
Philip Martin Arlen, Massimo Fantini, Justin David, Christina M. Annunziata, Kwong Y. Tsang, Pia Morelli
Meeting Abstract
Oncology
Armin Ghobadi, Premal Thaker, David Weng, Julie Vanas, Irene Ekwede, Mira Pavlova, Robert Keefe, Michael Kuo, Claudio Dansky Ullmann, Raffit Hassan, Christina Annunziata